Table 1.
Clinicopathological characteristics of UCC patients and association with pre-treatment sHE4 levels.
| sHE4 pmol/L | |||||
|---|---|---|---|---|---|
| Variables | No. of patients (%) | Geometric mean (SD) | Median (IQR) | FC (CI95%) | p-value |
| All patients | 109 (100%) | 56.3 (2.02) | 46.7 (28.8) | – | |
| Age (years) | 0.089 | ||||
| <48 | 47 (43%) | 45.5 (1.62) | 44.8 (20.8) | 1 | |
| ≥48 | 62 (57%) | 66.2 (2.22) | 51.3 (46.6) | 1.16 (0.98; 1.37) | |
| Histological type | |||||
| Squamous carcinoma | 73 (67%) | 55.7 (1.95) | 47.7 (31.4) | 1 | 0.609 |
| Adenocarcinoma | 24 (22%) | 64.4 (2.51) | 45.4 (33.4) | 0.92 (0.73; 1.16) | |
| Adenosquamous carcinoma | 12 (11%) | 45.8 (1.25) | 45.4 (15.6) | 0.91 (0.67; 1.23) | |
| Grading WHO | |||||
| G1 | 10 (9%) | 40.6 (1.25) | 39.9 (10.5) | 1 | 0.271 |
| G2 | 34 (31%) | 51.2 (1.60) | 44.6 (24.5) | 1.17 (0.85; 1.61) | |
| G3 | 55 (51%) | 56.9 (2.13) | 48.0 (30.3) | 1.24 (0.91; 1.68) | |
| Unknown | 10 (9%) | 101.0 (2.85) | 96.6 (117.0) | – | |
| FIGO stage | |||||
| I | 67 (61%) | 45.2 (1.54) | 44.0 (21.3) | 1 | <0.001 |
| II | 26 (24%) | 50.2 (1.51) | 47.4 (18.2) | 1.06 (0.87; 1.28) | |
| III | 6 (6%) | 128.0 (1.93) | 135.0 (49.3) | 3.04 (2.13; 4.35) | |
| IV | 10 (9%) | 199.0 (3.00) | 131.0 (362.0) | 2.37 (1.78; 3.14) | |
| Clinical tumor size | |||||
| ≤ 4 cm | 49 (45%) | 43.4 (1.51) | 41.1 (22.3) | 1 | 0.090 |
| >4 cm | 35 (32%) | 63.6 (1.88) | 48.0 (59.8) | 1.18 (0.98; 1.41) | |
| Unknown | 25 (23%) | 79.1 (2.76) | 52.7 (55.3) | – | |
| Lymph-vascular space invasion | |||||
| Absent | 17 (16%) | 42.2 (1.70) | 43.5 (22.0) | 1 | 0.338 |
| Present | 37 (34%) | 43.9 (1.38) | 41.1 (16.6) | 0.91 (0.76; 1.10) | |
| Unknown | 55 (50%) | 72.7 (2.30) | 55.7 (70.8) | – | |
| Stromal Infiltration | |||||
| <3 mm | 5 (5%) | 48.7 (1.28) | 51.2 (15.3) | 1 | 0.425 |
| ≥3 mm | 48 (44%) | 41.9 (1.51) | 39.0 (17.6) | 0.86 (0.59; 1.25) | |
| Unknown | 56 (51%) | 73.4 (2.27) | 56.2 (66.2) | – | |
| Parametrial invasion | |||||
| Absent | 47 (43%) | 42.0 (1.51) | 39.2 (21.5) | 1 | 0.261 |
| Present | 9 (8%) | 48.3 (1.24) | 47.7 (8.0) | 1.13 (0.91; 1.42) | |
| Unknown | 53 (49%) | 74.8 (2.31) | 56.7 (76) | – | |
| Vaginal invasion | |||||
| Absent | 43 (39%) | 41.3 (1.52) | 39.2 (13.3) | 1 | 0.071 |
| Present | 14 (13%) | 48.7 (1.28) | 49.8 (17.9) | 1.18 (0.99; 1.41) | |
| Unknown | 52 (48%) | 75.6 (2.32) | 56.7 (76.5) | – | |
| Lymph nodes status | |||||
| Negative | 39 (36%) | 43.6 (1.53) | 40.3 (23.0) | 1 | 0.957 |
| Positive | 18 (16%) | 43.9 (1.35) | 45.2 (14.1) | 1.00 (0.84; 1.20) | |
| Unknown | 52 (48%) | 74.4 (2.34) | 56.2 (77.4) | – | |
| Treatment | |||||
| Surgery | 26 (24%) | 40.4 (1.58) | 38.4 (24.6) | 1 | <0.001 |
| Surgery + RT | 18 (16%) | 45.7 (1.39) | 44.0 (18.9) | 1.05 (0.75; 1.47) | |
| Surgery + CT | 5 (5%) | 40.9 (1.18) | 37.8 (12.7) | 0.97 (0.57; 1.64) | |
| Surgery + CT + RT | 9 (8%) | 49.6 (1.44) | 52.0 (26.0) | 1.22 (0.80; 1.86) | |
| NACT + Surgery | 23 (21%) | 52.4 (1.49) | 47.7 (14.2) | 1.17 (0.85; 1.59) | |
| CT | 7 (6%) | 194.3 (2.89) | 135.4 (443.5) | 3.40 (2.14; 5.39) | |
| NACT + RT | 18 (16%) | 86.2 (2.59) | 83.4 (110.5) | 1.82 (1.31; 2.54) | |
| RT | 3 (3%) | 63.9 (1.88) | 84.0 (68.8) | 1.72 (0.89; 3.34) | |
| Persistence of disease | |||||
| No | 83 (76%) | 46.9 (1.55) | 44.4 (22.0) | 1 | <0.001 |
| Yes | 25 (23%) | 101.0 (2.81) | 89.7 (96.4) | 1.48 (1.22; 1.80) | |
| Unknown | 1 (1%) | 112.0 (–) | 112.0 (–) | ||
Results are reported as estimated Fold Change (FC) from robust linear models with asymptotic CI95%.
Robust F-test p-value; Bold numbers indicate a statistically significant difference with a p < 0.05.
CT, chemotherapy; RT, radiotherapy; NACT, neoadjuvant-CT.